This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).
Age 18 years or older.
No prior systemic treatment for lymphoma, except short-term corticosteroids for symptom control.
Life expectancy of more than 3 months.
Eastern Cooperative Oncology Group performance status of 0 to 2.
Aggressive NK-cell leukemia.
Significant dysfunction of major organs.
Known hypersensitivity to any study drug or its components, or contraindication to any study treatment.
Pregnant or breastfeeding women, or participants of childbearing potential unwilling to use effective contraception.